Teva Pharma Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
322 result(s) found, displaying 11 to 20
-
Cancellation by sponsorRequested by Teva Pharma Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MISTY-DUO ALLERGY azelastine (as hydrochloride) 125 microgram and fluticasone propionate 50 microgram nasal spray bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BI-EASE DUO ALLERGY azelastine (as hydrochloride) 125 microgram and fluticasone propionate 50 microgram nasal spray bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PALIPERIDONE-TEVA paliperidone (as palmitate) 25 mg/0.25 mL modified release suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PALIPERIDONE-TEVA paliperidone (as palmitate) 50 mg/0.50 mL modified release suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PALIPERIDONE-TEVA paliperidone (as palmitate) 150 mg/1.5 mL modified release suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PALIPERIDONE-TEVA paliperidone (as palmitate) 75 mg/0.75 mL modified release suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PALIPERIDONE-TEVA paliperidone (as palmitate) 100 mg/1.0 mL modified release suspension for injection pre-filled syringe.
-
Prescription medicine registrationActive ingredients: azelastine hydrochloride, fluticasone propionate.
-
Australian Public Assessment Report (AusPAR)Radicava (edaravone) was approved to treat adults with a diagnosis of amyotrophic lateral sclerosis who are independent in activities of daily living with normal respiratory function and where treatment is initiated within two years of disease onset.